» Articles » PMID: 36707860

The Complementary Roles of Genome-wide Approaches in Identifying Genes Linked to an Inherited Risk of Colorectal Cancer

Overview
Publisher Biomed Central
Specialty Oncology
Date 2023 Jan 28
PMID 36707860
Authors
Affiliations
Soon will be listed here.
Abstract

The current understanding of the inherited risk of colorectal cancer (CRC) started with an observational clinical era in the late 19 century, which was followed by a genetic era starting in the late 20 century. Genome-wide linkage analysis allowed mapping several high-risk genes, which marked the beginning of the genetic era. The current high-throughput genomic phase includes genome-wide association study (GWAS) and genome-wide sequencing approaches which have revolutionized the conception of the inherited risk of CRC. On the one hand, GWAS has allowed the identification of multiple low risk loci correlated with CRC. On the other, genome-wide sequencing has led to the discovery of a second batch of high-to-moderate-risk genes that correlate to atypical familial CRC and polyposis syndromes. In contrast to other common cancers, which are usually dominated by a polygenic background, CRC risk is believed to be equally explained by monogenic and polygenic architectures, which jointly contribute to a quarter of familial clustering. Despite the fact that genome-wide approaches have allowed the identification of a continuum of responsible high-to-moderate-to-low-risk variants, much of the predisposition and familial clustering of CRC has not yet been explained. Other genetic, epigenetic and environmental factors might be playing important roles as well. In this review we aim to provide insights on the complementary roles played by different genomic approaches in allowing the current understanding of the genetic architecture of inherited CRC.

Citing Articles

Impact of gout on colorectal cancer and its survival: a two-sample Mendelian randomization study.

Wei L, Song Y, Lan D, Miao X, Lin C, Yang S Discov Oncol. 2024; 15(1):819.

PMID: 39708204 PMC: 11663203. DOI: 10.1007/s12672-024-01714-6.


Drug development advances in human genetics-based targets.

Zhang X, Yu W, Li Y, Wang A, Cao H, Fu Y MedComm (2020). 2024; 5(2):e481.

PMID: 38344397 PMC: 10857782. DOI: 10.1002/mco2.481.

References
1.
Lucci-Cordisco E, Amenta S, Panfili A, Del Valle J, Capella G, Pineda M . Variants of uncertain significance (VUS) in cancer predisposing genes: What are we learning from multigene panels?. Eur J Med Genet. 2021; 65(1):104400. DOI: 10.1016/j.ejmg.2021.104400. View

2.
Dukes C . Familial intestinal polyposis. Ann Eugen. 1952; 17(Part 1):1-29. DOI: 10.1111/j.1469-1809.1953.tb02531.x. View

3.
Berry J, Polski A, Cavenee W, Dryja T, Murphree A, Gallie B . The Story: Characterization and Cloning of the First Tumor Suppressor Gene. Genes (Basel). 2019; 10(11). PMC: 6895859. DOI: 10.3390/genes10110879. View

4.
Botstein D, Risch N . Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet. 2003; 33 Suppl:228-37. DOI: 10.1038/ng1090. View

5.
Valle L, de Voer R, Goldberg Y, Sjursen W, Forsti A, Ruiz-Ponte C . Update on genetic predisposition to colorectal cancer and polyposis. Mol Aspects Med. 2019; 69:10-26. DOI: 10.1016/j.mam.2019.03.001. View